source
- Sarepta appoints former AbbVie executive Michael Severino as new CEO to drive turnaroundSarepta Therapeutics announced that Michael Severino will become its chief executive officer on July 28, succeeding Doug Ingram who plans to retire. Severino brings more than two decades of experi…
- FDA doubts efficacy of Capricor’s Duchenne stem-cell therapy after Phase 3 missThe U.S. Food and Drug Administration said Monday that Capricor Therapeutics’ stem‑cell treatment for Duchenne muscular dystrophy failed to meet the primary goals of its Phase 3 trial, contradictin…